Optimizing Tumor-Infiltrating Lymphocyte (TIL) Harvest Site and Patient Selection With CD8-PET Imaging in Patients With

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Crefmirlimb — DRUG
Given by Iv
PET/CT imaging — DEVICE
An additional excision, for research purposes only, will be performed from the site with the highest CD8 PET SUVmean as long as it is a dermal, subcutaneous, soft tissue, or nodal metastasis that does not require entry into the abdomen or pelvis and does not correspond to the planned standard-of-care harvest site.

To find out if the amount of CD8 immune cells at the place where TIL cells are collected is linked to how well a patient responds to treatment.

Experimental: Treatment with Crefmirlimab (IV)
Patients will undergo baseline research evaluation with a single crefmirlimab infusion on Day 0

safety and adverse events (AEs) [ Time Frame: Through study completion; an average of 1 year. ]

Facility	City	State	ZIP	Site coordinators
UT MD Anderson Cancer Center	Houston	Texas	77030	Ashley M Holder, MD [email protected] 713-794-1001 Ashley M Holder, MD (PRINCIPAL_INVESTIGATOR)

By research site